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Abstract
Many solid cancers are known to exhibit a high degree of heterogeneity in their deregulation of different oncogenic
pathways. We sought to identify major oncogenic pathways in gastric cancer (GC) with significant relationships to patient
survival. Using gene expression signatures, we devised an in silico strategy to map patterns of oncogenic pathway activation
in 301 primary gastric cancers, the second highest cause of global cancer mortality. We identified three oncogenic pathways
(proliferation/stem cell, NF-kB, and Wnt/b-catenin) deregulated in the majority (.70%) of gastric cancers. We functionally
validated these pathway predictions in a panel of gastric cancer cell lines. Patient stratification by oncogenic pathway
combinations showed reproducible and significant survival differences in multiple cohorts, suggesting that pathway
interactions may play an important role in influencing disease behavior. Individual GCs can be successfully taxonomized by
oncogenic pathway activity into biologically and clinically relevant subgroups. Predicting pathway activity by expression
signatures thus permits the study of multiple cancer-related pathways interacting simultaneously in primary cancers, at a
scale not currently achievable by other platforms.
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Introduction
Gastric cancer (GC) is the second leading cause of global cancer
mortality [1]. Particularly prevalent in Asia, most GC patients are
diagnosed with advanced stage disease [2]. Deregulation of
canonical oncogenic pathways such as E2F, K-RAS, p53, and
Wnt/b-catenin signaling are known to occur with varying
frequencies in GC [3–6], indicating that GC is a molecularly
heterogeneous disease. Previous studies describing GC diversity in
primary tumors have typically focused on single pathways,
measuring only one or a few biomarkers per experiment [4,6,7].
In contrast, experimental evidence indicates that most cancer
phenotypes (uncontrolled growth, resistance to apoptosis, etc) are
largely governed not just by single pathways, but complex
interactions between multiple pro- and anti-oncogenic signaling
circuits [8]. Narrowing this gap between the clinical and
experimental arenas will require strategies capable of measuring
and relating activity patterns of multiple oncogenic pathways
simultaneously in primary tumors.
Previous studies have proposed using gene expression signatures
to predict the activity of oncogenic pathways in cancers [9] – here,
we hypothesized that patterns of oncogenic pathway activation
could be used to develop a genomic taxonomy of GC.
Importantly, this pathway-centric strategy differs substantially
from previous microarray studies describing expression changes
associated with morphological and tissue type differences in GC
[10,11], as pathway signatures (rather than individual genes) are
used as the basis for cancer classification. We developed an in silico
method to map activation levels of different pathways in cohorts of
complex primary tumor profiles and validated this pathway-
directed classification approach using proof-of-concept examples
from breast cancer. We then applied this method to GC to
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evaluate eleven oncogenic pathways previously implicated in
gastric carcinogenesis [3–7,12–17]. In total, we analyzed over 300
primary GCs derived from three independent patient cohorts,
performing to the best of our knowledge the largest genomic
analysis of GC to date. We identified three oncogenic pathways
(nuclear factor-kB (NF-kB), Wnt/b-catenin, and proliferation/
stem cell) that were deregulated in the vast majority (.70%) of
GCs, and functionally validated the pathway predictions in vitro
using a panel of GC cell lines. Although patient stratification at the
level of individual pathways failed to consistently demonstrate
significant differences in clinical outcome, patient stratification by
oncogenic pathway combinations (e.g. high proliferation/high NF-
kB vs. low proliferation/low NF-kB) showed reproducible and
significant survival differences in multiple independent patient
cohorts, suggesting a critical role for pathway combinations in
influencing GC clinical behavior. Our results thus demonstrate
that GCs can be successfully taxonomized using oncogenic
pathway activity into biologically, functionally, and clinically
relevant subtypes.
Results
Predicting Pathway Activation in Cancer Gene Expression
Profiles
Our strategy for predicting levels of oncogenic pathway
activation in cancers involves four steps (Figure 1A). First, we
defined ‘pathway signatures’ - sets of genes exhibiting altered
expression after functional perturbation of a specific pathway in a
well-defined in vitro or in vivo experimental system. Second, we
mapped the pathway signatures onto gene expression profiles from
a heterogeneous series of cancers. Third, using a nonparametric,
rank-based pattern matching procedure, activation scores were
assigned to individual cancers based upon the strength of
association to the pathway signature. Finally, the individual
cancers were sorted based upon their pathway activation scores.
Before applying this approach to GC, we considered it
important to validate this in silico strategy in a series of proof-of-
principle experiments. We chose the example of breast cancer, a
malignancy for which there is ample evidence of pathway
heterogeneity and discrete ‘molecular subtypes’ [18]. To perform
this validation, we first asked if previously described pathway
signatures associated with impaired estrogen signaling could be
used to identify breast cancer cell lines exhibiting high levels of
estrogen receptor (ER) activity. We analyzed a gene expression
panel of 51 breast cancer cell lines originally described in Neve at
al. [18] with an 11-gene ‘tamoxifen sensitivity’ pathway signature
derived from a list of genes differentially expressed between MaCa
3366, a tamoxifen-sensitive human mammary carcinoma xeno-
graft, and MaCa 3366/TAM, a tamoxifen-resistant subline of the
same xenograft [19]. We found that breast cancer cell lines
positively associated with the tamoxifen sensitivity signature
exhibited significantly higher expression levels of ESR1, the
estrogen receptor and molecular target of tamoxifen, compared
to lines showing negative pathway activation scores
(p = 2.1261027, Accuracy 84.3%, Sensitivity 100%, Specificity
75%) (Figure 1B and Table S1).
Second, we tested if a pathway signature associated with
estrogen signaling but derived from non-breast tissue could also be
used to stratify the same panel of breast cancer cell lines. We
queried the breast cancer cell line panel with a 41-gene ‘estrogen
response’ signature derived from a list of genes upregulated by
estradiol in U2OS human osteosarcoma cells [20]. Despite the
signature originating from a different tissue type (e.g. osteosarco-
ma), we once again found that, when sorted based upon their
predicted estrogen responsiveness, breast cancer cell lines clustered
together by their level of ESR1 (estrogen receptor) expression
(p = 0.0035, Accuracy 62.7%, Sensitivity 94.7%, Specificity
43.8%) (Figure 1C and Table S1). These results demonstrate that
it is indeed feasible to predict patterns of pathway activation in a
particular cancer of interest (gastric cancer in our cases) using
expression signatures obtained from different experimental
conditions and even different tissue types.
Patterns of Oncogenic Pathway Activation in GC
After validating this pathway prediction approach, we proceed-
ed to apply the strategy to primary GC. Rather than testing every
possible pathway, we selected eleven oncogenic and tumor
suppressor pathways previously implicated in gastric carcinogen-
esis, using in our analysis RAS [4], p53 [5], BRCA1 [12], p21
[13], Wnt/b-catenin [6], E2F [3], SRC [14], MYC [15], NF-kB
[21], histone deacetylation (HDAC) [16], and stem-cell related
signatures [17]. Whenever possible, we attempted to select
multiple signatures for each pathway, preferably from independent
published studies. For example, of the two E2F activation
signatures used in our approach, one signature was obtained by
inducing E2F1 activity in rat fibroblast cells [22] while the other
signature was obtained using an osteosarcoma-derived cell line
containing an inducible ER-E2F1 fusion protein [23]. Final
pathway predictions for further analyses were typically obtained by
combining individual signatures belonging to the same pathway
(see Materials and Methods).
We computed activation scores for the eleven pathways
represented by 20 pathway signatures across three independent
cohorts of primary GCs derived from Australia (Cohort 1–70
tumors), Singapore (Cohort 2–200 tumors), and the United
Kingdom (Cohort 3–31 tumors). To visualize patterns of pathway
activation, we depicted each cohort as a heatmap, where the
heatmap color represents the predicted strength of activation for
each pathway in the individual GCs. We observed considerable
heterogeneity of pathway activation between individual GC
patients (Figure 2A–2C). However, signatures derived from
independent studies representing similar pathways frequently
yielded similar prediction patterns (e.g. NF-kB (skin) and NF-kB
(cervix)), and a chi-square test confirmed a significant level of
Author Summary
Gastric cancer is the second leading cause of global cancer
mortality. With current treatments, less than a quarter of
patients survive longer than five years after surgery.
Individual gastric cancers are highly disparate in their
cellular characteristics and responses to standard chemo-
therapeutic drugs, making gastric cancer a complex
disease. Pathway based approaches, rather than single
gene studies, may help to unravel this complexity. Here,
we make use of a computational approach to identify
connections between molecular pathways and cancer
profiles. In a large scale study of more than 300 patients,
we identified subgroups of gastric cancers distinguishable
by their patterns of driving molecular pathways. We show
that these identified subgroups are clinically relevant in
predicting survival duration and may prove useful in
guiding the choice of targeted therapies designed to
interfere with these molecular pathways. We also identi-
fied specific gastric cancer cell lines mirroring these
pathway subgroups, which should facilitate the pre-clinical
assessment of responses to targeted therapies in each
subgroup.
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similarity in the overall patterns of pathway activation between the
Australia and Singapore cohorts (p = 0.00038), and between the
Australia and UK cohorts (p = 0.00051, see Table S2) suggesting
that the GC pathway predictions are not tied to a specific patient
cohort. We identified two major clusters of co-activated pathways,
which were completely preserved in Cohorts 1 and 2 (Figure 2A
and 2B) and mostly preserved in Cohort 3 (Figure 2C). These
included (i) a ‘proliferation/stem cell’ pathway cluster (brown
vertical bar in Figure 2) encompassing pathways associated with
various cell cycle regulators (e.g. MYC, E2F, p21) and stem cell
signatures; and (ii) an ‘oncogenic signaling’ pathway cluster (grey
vertical bar in Figure 2) containing many different oncogenic
pathways (BRCA1, NF-kB, p53, Wnt/b-catenin, SRC, RAS, and
HDAC pathways).
Figure 1. Predicting pathway activation in cancers using gene expression signatures. (A) Schematic of the pathway prediction workflow. I)
Expression profiles of a set of cancer samples are pre-processed to identify differentially expressed genes (red and green) compared against a
common reference. II) A pathway signature is derived from an independent study concerning the cellular pathway of interest. III) The cancer profiles
are compared to the pathway signature using connectivity metrics [37], and subsequently sorted against one another according to the strength of
pathway association (pathway scoring). (B) Pathway predictions in breast cancers using a breast-derived tamoxifen sensitivity signature are
corroborated by ESR1 (estrogen receptor) expression, which was used to determine estrogen receptor (ER) status (ER-positive or ER-negative). The
cancer profiles are a collection of 51 breast cancer cell lines [18], and the pathway signature generated by comparing a tamoxifen-sensitive mammary
xenograft (MaCa 3366) to its tamoxifen-resistant subline (MaCa 3366/TAM) [19]. (C) Pathway predictions in breast cancers using an osteosarcoma-
derived estrogen response signature are corroborated by ESR1 (estrogen receptor) expression. The cancer profiles are a collection of 51 breast cancer
cell lines [18], and the pathway signature generated by identifying genes upregulated by estradiol in U2OS osteosarcoma cells [20]. P-values were
computed using Pearson’s chi-square test, under the null hypothesis that the pathway predictor delivers comparable performance to a random
predictor. The ESR1 gene is absent from both the 11-gene tamoxifen sensitivity signature and the 41-gene estrogen response signature. Only a two-
gene overlap exists between both signatures.
doi:10.1371/journal.pgen.1000676.g001
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In Vitro Validation of Pathway Predictions
By analyzing the GC pathway heatmap in Figure 2, we selected
three oncogenic pathways (NF-kB, Wnt/b-catenin, and prolifer-
ation/stem cell) that were individually activated in a significant
proportion of GCs ($35%), and when combined provided
coverage of the majority (.70%) of GCs. Proliferation/stem cell
pathways were activated in 40% of GCs in each cohort (range: 38
to 43%), Wnt/b-catenin pathways were activated in 46% of GCs
(range: 43 to 48%), and the NF-kB pathway was activated in 39%
of GCs (range: 35 to 41%) (color bars below each heatmap in
Figure 2). These frequencies and other frequently deregulated
pathways (e.g. p53) are listed in Table S3.
To experimentally validate these primary GC pathway
predictions, we applied the pathway prediction algorithm to a
panel of 25 GC cell lines (GCCLs) (Figure 3). Similar to primary
GC, ‘proliferation/stem cell’ and ‘oncogenic signaling’ pathway
clusters were also observed in the GCCLs. Furthermore,
signatures representing the same pathway, but obtained from
different studies, such as the two independent MYC-derived
signatures [9,24] also clustered together in the GC cell lines after
Figure 2. Patterns of pathway activation in primary gastric cancers. Twenty gene expression signatures representing 11 cancer-related
pathways (MYC, p21-repression, E2F, NF-kB, RAS, Wnt/b-catenin, SRC, BRCA1, p53, HDAC inhibition, stem cell) were queried against 301 primary
gastric cancer gene expression profiles from three independent patient cohorts—(A) Australia, (B) Singapore, and (C) United Kingdom. Each heatmap
depicts the activation scores of pathways represented by the signatures (rows) in individual tumors (columns), with red squares denoting higher
activation scores. Both pathways and primary tumors were ordered using unsupervised hierarchical clustering. Pathways related to proliferation or
stem cell form a distinct cluster (brown) from other pathways (grey). Tumors with high predicted activation of NF-kB (purple), Wnt/b-catenin (yellow),
or proliferation/stem cell-related pathways (blue) are indicated by the relevant color bars at the bottom of the heatmaps. Individual signatures that
represent similar pathways are differentiated by the wordings within brackets. E.g. Stem cell (hESC): human embryonic stem cell vs. Stem cell (mESC):
mouse embryonic stem cell vs. Stem cell (mNSC): mouse neural stem cell; HDAC inhibition (TSA): trichostatin A vs. HDAC inhibition (BUT): butyrate.
doi:10.1371/journal.pgen.1000676.g002
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unsupervised hierarchical clustering (purple brackets in Figure 3).
Guided by the pathway predictions, we identified specific GC cell
lines exhibiting patterns of oncogenic pathway activity mirroring
primary GCs. Confidence in the selection of specific cell lines as in
vitro models was also achieved by repeating the prediction
procedure seven times using a variety of reference profiles,
ranging from the median GCCL profile to independent profiles
such as non-malignant normal stomach profiles (see Materials and
Methods and Table S4). Pairwise comparisons confirmed that any
two reference profiles were more likely to produce concurring
pathway predictions than conflicting predictions (Text S1 and
Table S4). Some examples of representative lines include AZ521
and MKN28 cells, which exhibit activation of proliferation/stem
cell pathways, YCC3 and AGS cells for Wnt/b-catenin pathways,
and MKN1 and SNU5 cells for the NF-kB pathway.
First, we directly measured the proliferative rates of 22 GCCLs
and correlated the proliferation rate data with the mean activation
score from signatures in the proliferation/stem cell pathway
cluster. There was a significant association between the experi-
mentally determined proliferative rates and the pathway activation
scores (R= 0.4688, p= 0.0278) (Figure 4A). Supporting the notion
that oncogenic pathway signatures are superior predictors of
pathway activity compared to the expression of single key pathway
genes, no significant associations were observed for either MYC or
E2F1 expression (p= 0.48 and 0.38 for MYC and E2F1,
respectively) (Figure S1).
Second, in order to validate the Wnt/b-catenin pathway
predictions, we analyzed the expression of various Wnt pathway
components (b-catenin, TCF4) and relative levels of TCF/LEF
transcriptional activity in GC cell lines predicted to be Wnt/b-
catenin- activated or Wnt/b-catenin-nonactivated. Of seven cell
lines selected for their experimental tractability (e.g. ease of
transfection and convenient growth conditions), we found that both
b-catenin and the TCF/LEF transcription factor TCF4 (also known
as TCF7L2), major components of the Wnt signaling pathway, were
expressed in GC cell lines predicted by the pathway activation
analyses to have high Wnt/b-catenin activity (AGS, YCC3, Kato
III, and NCI-N87), but not expressed in two out of three lines
(SNU1 and SNU5) associated with inconsistent or low Wnt/b-
catenin activation scores (Figure 4B). Furthermore, in order to
directly assay Wnt pathway activity, we determined TCF/LEF
transcriptional activity in the GC cell lines using Topflash, a
luciferase expressing plasmid containing multimerized TCF binding
sites. The Topflash assay confirmed high TCF/LEF transcriptional
activity in three out of four GC cell lines predicted to have high
Wnt/b-catenin activity (AGS, YCC3, and Kato III), but minimal or
no Topflash activity in GC cell lines associated with inconsistent or
low Wnt/b-catenin activation scores (SNU1, SNU5, and SNU16).
Additionally, the b-catenin pathway activation scores were
significantly higher in GCCLs with more than two-fold TCF/
LEF transcriptional activity (AGS, YCC3, Kato III, and NCI-N87)
than in GCCLs with lower TCF/LEF transcriptional activity
(p= 0.007, Figure 4B). When compared against single genes,
superior associations to TCF/LEF transcriptional activity were
once again observed using the mean activation score from Wnt/b-
catenin signatures compared to either b-catenin or TCF4 (aka
TCF7L2) expression alone (p= 0.038 for signatures vs. p = 0.31 and
0.58 for b-catenin and TCF4, respectively) (Figure S1).
Third, to validate the NF-kB pathway predictions, we selected
11 GCCLs consistently predicted as either NF-kB-activated (‘NF-
Figure 3. Patterns of pathway activation in gastric cancer cell lines. Twenty gene expression signatures representing 11 cancer-related
pathways (previously described in Figure 2) were queried against a panel of 25 gastric cancer cell lines. The heatmap depicts the activation scores of
pathways represented by the signatures (rows) in individual cell lines (columns), with red squares denoting higher activation scores. Pathways and
cell lines were ordered using unsupervised hierarchical clustering. Similar to primary tumors, pathways related to proliferation or stem cell form a
distinct cluster (brown) from other pathways (grey). Cell lines with high predicted activation of NF-kB, Wnt/b-catenin, or proliferation/stem cell-
related pathways are indicated by relevant color bars at the bottom of the heatmap. For the proliferation/stem cell-related signatures, the cell lines
were mean-normalized relative to one another against the mean activation score, as all cell lines scored positive for proliferation/stem cell-related
pathways.
doi:10.1371/journal.pgen.1000676.g003
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kB/on’, six GCCLs) or NF-kB-nonactivated (‘NF-kB/off’, five
GCCLs) (Figure S2). Increased gene expression of p50 and p65,
the NF-kB heterodimer subunits, were observed in NF-kB/on GC
cell lines compared to NF-kB/off GC cell lines (p = 0.0002 for
p50, p= 0.046 for p65, Figure 4C) and at the protein level p65
expression was observed largely in the NF-kB/on lines (Figure 4C).
Using immunocytochemistry on formalin fixed paraffin embedded
GC cell lines, p65 protein expression was more frequently
observed in NF-kB/on GC cell lines compared to NF-kB/off
GC cell lines in terms of nuclear sublocalization, percentages of
cells with staining (either nuclear or cytoplasmic), and staining
intensity (Table S5, Figure S3). To determine if NF-kB/on GC
cell lines also exhibited differential expression of p65-regulated
genes compared to NF-kB/off GC cell lines, we combined the list
Figure 4. Experimental validation of pathway predictions in gastric cancer cell lines. (A) Experimental validation of proliferation/stem cell
pathway predictions. The graph depicts the experimentally measured proliferative capacities of 22 cell lines (y-axis) against the mean proliferation/
stem cell activation scores derived from signatures belonging to the proliferation/stem cell cluster. (B) Experimental validation of Wnt/b-catenin
pathway predictions. The bottom graph shows the predicted activation levels of the Wnt (grey bars) and b-catenin (blue bars) pathways across seven
cell lines. Lines predicted to be active exhibit expression of canonical Wnt pathway components b-catenin and TCF4 (aka TCF7L2) (middle
immunoblot), and higher TCF4 transcriptional activity (top graph) compared to lines associated with inconsistent or low Wnt/b-catenin activation
scores. Immunoblots were normalized using a b-actin antibody. Parts of this figure were previously presented [50] for a different purpose. (C,D)
Experimental validation of NF-kB pathway predictions. (C) The bottom graph shows predicted NF-kB activation levels across 11 cell lines. Lines
predicted to be active (‘NF-kB/on’) exhibit significantly higher p65 and p50 mRNA expression levels (topmost graph) and p65 protein expression
(immunoblot) relative to lines predicted to be nonactivated (‘NF-kB/off’). All lines exhibit comparable p50 protein expression. Immunoblots were
normalized using a GAPDH antibody. Whether p65 target genes are over- or under-expressed in ‘NF-kB/on’ lines compared to ‘NF-kB/off’ lines
depends on whether they were up- or downregulated by TNF-a [26], an inducer of NF-kB activation (bottom heatmap). (D) NF-kB activity in cell lines.
‘NF-kB/on’ lines exhibit significantly higher NF-kB transcriptional activity compared to ‘NF-kB/off’ lines.
doi:10.1371/journal.pgen.1000676.g004
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of genes directly bound by the p65 transcription factor [25] with
lists of genes regulated at the mRNA level by TNF-a [26], a
known inducer of NF-kB activation. Using Gene Set Enrichment
Analysis (GSEA, [27]), we found that p65 target genes upregulated
by TNF-a treatment were significantly overexpressed in NF-kB/
on GC cell lines compared to NF-kB/off GC cell lines (normalized
enrichment score, NES= 1.86; false discovery rate, FDR,0.001,
bottom most panel, Figure 4C). Conversely, p65 target genes
downregulated by TNF-a were significantly underexpressed in
NF-kB/on GC cell lines compared to NF-kB/off GC cell lines
(NES=21.56, FDR=0.019, bottom most panel, Figure 4C).
Finally, to directly confirm the presence of elevated NF-kB
activity, we transfected three NF-kB/on GC cell lines and two NF-
kB/off GC cell lines with a luciferase reporter containing a NF-kB
reporter gene. As shown in Figure 4D, the three NF-kB/on GC
cell lines exhibited elevated NF-kB transcriptional activity
compared to the two NF-kB/off GC cell lines (p = 0.0084).
Taken collectively, these results support the concept that in silico
pathway predictions using gene expression profiles are associated
with activation of the relevant pathway in vitro.
Pathway Combinations Predict Gastric Cancer Patient
Survival
To assess the clinical relevance of the identified pathway
subgroups, we investigated if patterns of pathway co-activation as
illustrated in the heatmaps of the different cohorts might be related
to patient survival. We used overall survival data from Cohort 1
and Cohort 2 and stratified patients by their predicted patterns of
pathway activation. A primary GC profile was defined as showing
high activation level of a pathway when the activation score was
above zero – i.e. being positively associated with the pathway
signature. Patient groups stratified by either the proliferation/stem
cell pathway activation score alone or the NF-kB pathway
activation score alone did not differ significantly regarding their
overall survival (p.0.05 for proliferation/stem cell and NF-kB in
both cohorts, Figure 5A and 5B). However, when the pathway
activation scores were combined, patients with high activation
levels of both NF-kB and proliferation/stem cell pathways had
significantly shorter survival compared to patients with low
activation levels of both NF-kB and proliferation/stem cell
pathways (p = 0.0399 and p= 0.0109 for Cohorts 1 and 2
respectively, Figure 5D).
Activation of the Wnt/b-catenin pathway was significantly
associated with patient survival in Cohort 1, (p = 0.0056,
Figure 5C) but not in Cohort 2 (p = 0.0693, Figure 5C). However,
patients in Cohorts 1 and 2 with high activation levels of both
Wnt/b-catenin and proliferation/stem cell pathways had signifi-
cantly worse survival compared to patients with low activation
levels of both pathways (p = 0.0073 and p=0.0086, Figure 5E). To
benchmark the contributions of the pathway combinations against
known histopathologic criteria, we performed a multivariate
analysis including combined pathway predictions and pathological
tumor stage (TNM classification: stages 1–4), the most important
prognostic factor in GC [28]. In both cohorts, combined
activation of proliferation/stem cell and NF-kB pathways proved
to be a prognostic factor independent from tumor stage (p= 0.003
and 0.048 for Cohorts 1 and 2, respectively) (Table S6). Likewise,
combined activation of proliferation/stem cell and Wnt/b-catenin
pathways was an independent prognostic factor in Cohort 1 and
achieved borderline significance in Cohort 2 (p,0.001 and
p= 0.058, Table S7). These results demonstrate that the
assessment of the combined pathway activation status is clinically
relevant and moreover can provide additional prognostic infor-
mation over and above the current gold standard of patient
prognosis prediction, the TNM based tumor staging.
Discussion
In this study, we sought to subdivide GCs into molecularly
homogenous subgroups as a first step to individualizing patient
treatments and improving outcomes. Importantly, unlike previous
GC microarray studies relating gene expression patterns to
histology or anatomical type [10,11], we chose to base our GC
subdivisions on patterns of oncogenic pathway activity. After
developing and validating this novel classification approach, we
were able to describe, for the first time, a genomic taxonomy of
GC based on patterns of oncogenic pathway activity. Our
approach is particularly suited for gene expression microarrays,
since these platforms interrogate thousands of mRNA transcripts
in each sample, thereby permitting the assessment of multiple
pathways simultaneously in a single experiment. In contrast, such
an approach is not currently possible at the protein level due to
lack of appropriate platforms. Using this strategy, we identified
three dominant pathways showing activation in the majority
(.70%) of GCs: proliferation/stem cell, Wnt/b-catenin, and NF-
kB signaling.
The ability to perform such ‘‘high-throughput pathway
profiling’’ opens many interesting avenues. For example, several
studies have previously reported inconsistent results regarding the
prognostic impact of different oncogenic pathways in GC - the
prognostic implications of proliferation-related antigens such as
Ki-67 in GC are not firmly established [29], and high NF-kB
activation in GC has been associated with both good and bad GC
patient outcome in different studies [7,30]. It is quite possible that
some of this inconsistency may have been due to a historical focus
on using conventional methods and analyzing either single
pathways or individual pathway components (genes/proteins).
Our observation that pathway combinations are predictive of
patient outcome suggests that pathway combinations, rather than
single pathways alone, may play a critical role in influencing tumor
behavior.
Another benefit of high-throughput pathway profiling is the
ability to define higher order relationships between distinct
oncogenic pathways. In the current study, we consistently
observed concomitant activation of E2F, MYC, p21(-repression),
and stem cell pathways in tumors (the ‘proliferation/stem cell’
pathway cluster). This is most likely due to increased cellular
proliferation in tumor cells, as E2F is important in cell
proliferation control and MYC is both a p21-repressor and
inducer of cyclin D2 and cyclin-dependent kinase binding protein
CksHs2 [31]. Furthermore, stem cells, particularly embryonic
stem cells (ESCs), are also known to exhibit high cell proliferation
rates [32]. More intriguingly, we also observed close associations
between apparently functionally different pathways, such as b-
catenin and SRC, as well as HDAC inhibition and BRCA1. Such
pathway co-activation patterns may suggest functional interactions
between these pathways, which deserve to be studied further. For
example, it is possible that activated c-SRC may enhance the
expression of the Wnt signaling pathway [33]. Exploring the
relationships between pathways showing co-activation may thus
provide valuable information regarding the ability of the cancer
cell to coordinate the activity of multiple pathways.
A third benefit of the pathway profiling approach is that it
facilitates identification of major disease-related pathways. Of the
pathways analyzed in this study, the finding that NF-kB signaling
may be elevated in a significant proportion of GCs deserves some
attention as this pathway has been relatively less explored in GC.
Oncogenic Pathway Activity in Gastric Cancer
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Interestingly, while we observed a significant difference in both
p50 and p65 (the NF-kB subunits) gene expression between NF-
kB/on and NF-kB/off GCCLs, we did not observe overt
differential p50 protein expression in these lines, in contrast to
p65 (Figure 4C). This may be due to a combination of three
reasons. First, the absolute range of p65 gene expression across the
cell lines is markedly greater than the absolute range of p50 gene
expression (.36, Figure S4). Second, the Western blotting assay
used to perform these protein measurements is known to be highly
non-quantitative, which may mask subtle differences in expression.
Third, beyond gene expression, p50 expression is also subject to a
variety of post-transcriptional regulatory mechanisms such as
precursor cleavage that might affect the final level of p50 protein,
while p65 is not generated from a precursor protein [34]. NF-kB
has been shown to be activated by H. pylori [35], a known GC
carcinogen, and aberrant NF-kB signaling has also been
implicated in multiple inflammation-linked cancers such as GC
[36]. NF-kB has been suggested to be constitutively activated in
primary gastric cancers in a few studies [7]. Targeted NF-kB-
inhibitors are currently being actively developed in many
Figure 5. Pathway interactions influence patient survival in gastric cancer. Kaplan-Meier survival analysis of Australia and Singapore cohorts
(Heatmaps A and B in Figure 2) between patient groups stratified by predicted pathway activation status. Cohort 3 was not included in the survival
analysis as it is much smaller than Cohorts 1 and 2 (31 tumors compared to 70 and 200), making it unreliable for statistical analysis. (A–C) Effects of
individual pathways. Patients were stratified by (A) proliferation/stem cell signatures alone, (B) NF-kB signatures alone, and (C) Wnt/b-catenin
signatures alone. (D) and (E) Effects of pathway interactions. Patients were stratified by (D) NF-kB and proliferation/stem cell signatures, and (E) Wnt/
b-catenin and proliferation/stem cell signatures. For both the NF-kB and Wnt/b-catenin signatures, the significance of the survival difference or death
hazard was markedly enhanced by the addition of pathway prediction information from the proliferation/stem cell signatures. The outcome metric
was duration of overall survival. H: death hazard indicating the ratio of the mortality rate of patients showing high activation level of single pathway
(or both of two pathways) to the mortality rate of patients showing low activation level of single pathway (or both of two pathways). All death hazard
ratios are significant at p,0.01. CI0.95: 95% confidence intervals for death hazard ratio.
doi:10.1371/journal.pgen.1000676.g005
Oncogenic Pathway Activity in Gastric Cancer
PLoS Genetics | www.plosgenetics.org 8 October 2009 | Volume 5 | Issue 10 | e1000676
anticancer drug development programs and a subset of GC
patients (i.e. those with elevated NF-kB activity) may represent a
suitable subclass for evaluating the efficacy of these compounds.
The in silico method used in our study is conceptually similar to
the work of Bild et al, which used a binary regression model to
classify tumors based on the predicted activity of five oncogenic
pathways [9]. Unlike binary regression, our approach, which
makes use of a rank-based connectivity metric [37], requires no
elaborate training process on each pathway signature and also
does not require the availability of raw expression data, facilitating
the use of the many publicly available pathway signatures in the
literature [27]. However, the gene expression-based approach
does have limitations. First, because our pathway predictions are
based on gene expression rather than proteins, such predictions
are admittedly molecular surrogates of true pathway signaling
activity. Second, we are currently limited to analyzing known
oncogenic pathways previously identified in the literature. Third,
although we were able to use pathway signatures from very
different tissue contexts to predict pathway activation status, an
examination of the initial proof-of-principle breast cancer
examples revealed that the association of ER status to estrogen
responsiveness as predicted using the osteosarcoma signature,
although significant, was markedly weaker compared to the
association of ER status to tamoxifen sensitivity predicted using a
signature derived from the same tissue type (i.e. breast). This result
implies that there may also exist tissue-specific differences in
pathway signatures that may affect prediction accuracy. Fourth,
compared to our study which focused on pathways of known
biological relevance in GC, it is unclear if this method can be
applied to diseases where prior knowledge of involved pathways
may not be available. However, it should be noted that a wealth of
pathway signatures (.1000) associated with diverse biochemical
and signaling pathways already exists in the literature, which can
be accessed from public databases such as MSigDB (http://www.
broad.mit.edu/gsea/msigdb/genesets.jsp?collection=CGP). Since
our approach can be applied to virtually any disease dataset for
which gene expression information is available, testing every
signature in a high-throughput manner for evidence of pathway
deregulation is both conceivable and feasible. In such cases,
pathway exhibiting high frequencies of deregulation would then
represent candidate pathways involved in the disease in question,
which can then be targeted for focused investigation and
experimentation. Addressing these issues will form the ground for
much future research.
In conclusion, we have shown in this work that pathways
signatures can be successfully used to predict the activation status
of cellular signaling pathways, even in biological entities as
complex as a human GC. One obvious immediate application of
such pathway-based taxonomies may relate to the use of targeted
therapies. Initial trials assessing the role of targeted therapies in
GC have demonstrated only modest results [38]; however, most of
these studies have been performed without pre-stratifying patients
using molecular or histopathologic criteria. Pathway-based
taxonomies may prove very useful in developing personalized
treatment regimens for different subgroups of GC, since such
oncogenic pathway activation patterns can be readily linked to
potential pathway inhibitors and targeted therapies.
Materials and Methods
Primary Gastric Cancer Samples
Three cohorts of gastric cancer were profiled: Cohort 1–70
tumors (Peter MacCallum Cancer Centre, Australia), Cohort 2–200
tumors (National Cancer Centre, Singapore), and Cohort 3–31
tumors (Leeds Institute of Molecular Medicine, United Kingdom).
All GCs were collected with approvals from the respective
institutions, Research Ethics Review Committee, and signed patient
informed consent. Histopathological data of all GC cohorts are
provided in Table S8, S9, S10. The median follow-up period was
16.89 months for Cohort 1 and 13.47 months for Cohort 2. 43
patients from Cohort 1 and 91 from Cohort 2 were dead at the end
of the study period.
Gastric Cancer Cell Lines
A total of 25 unique GC cell lines were profiled. GC cell lines
AGS, Kato III, SNU1, SNU5, SNU16, NCI-N87, and Hs746T
were obtained from the American Type Culture Collection and
AZ521, Ist1, TMK1, MKN1, MKN7, MKN28, MKN45,
MKN74, Fu97, and IM95 cells were obtained from the Japanese
Collection of Research Bioresources/Japan Health Science
Research Resource Bank and cultured as recommended. SCH
cells were a gift from Yoshiaki Ito (Institute of Molecular and Cell
Biology, Singapore) and were grown in RPMI media. YCC1,
YCC3, YCC6, YCC7, YCC10, YCC11, and YCC16 cells were a
gift from Sun-Young Rha (Yonsei Cancer Center, South Korea)
and were grown in MEM supplemented with 10% fetal bovine
serum (FBS), 100 units/mL penicillin, 100 units/mL streptomycin,
and 2 mmol/L L-glutamine (Invitrogen).
RNA Extraction and Gene Expression Profiling
Total RNAwas extracted from cell lines and primary tumors using
Qiagen RNA extraction reagents (Qiagen) according to the
instructions of the manufacturer. Cell line and primary tumor
mRNAs from Cohort 1 and Cohort 2 were hybridized to Affymetrix
Human Genome U133 plus Genechips (HG-U133 Plus 2.0,
Affymetrix), while primary tumor mRNAs from Cohort 3 were
profiled using U133A Genechips (HG-U133A, Affymetrix). All
protocols were performed according to the instructions of the
manufacturer. Raw data obtained after chip-scanning was further
processed using the MAS5 algorithm (Affymetrix) available in the
Bioconductor package simpleaffy. The microarray data sets are
available at http://www.ncbi.nlm.nih.gov/projects/geo/ (Accession:
GSE15460).
Signatures of Pathway Activation
All signatures used in this study were previously generated
[9,19,20,22–24,39–49], and obtained from either the MSigDB
database [27] (http://www.broad.mit.edu/gsea/msigdb/genesets.
jsp?collection =CGP) or original references [9,39]. Detailed
descriptions of the signatures and their sources are available in
Table S11 and Table S12. Each signature is represented by a
geneset, termed a query signature (QS). Depending on the
signature, a QS may consist of only up- (or down-)regulated
genes, i.e. genes up- (or down-)regulated during the activation of
the pathway. It may also consist of both up- and down-regulated
genes. Our approach is capable of handling all of the
aforementioned types of QS. QSs were mapped to the probeset
domain of the cancer profiles (HG-U133A or HG-U133 Plus 2.0)
before computing the pathway activation scores for the cancer
profiles. Mapping of QSs were performed using the probe
mapping (‘.chip’) files available from ftp://gseaftp.broad.mit.
edu/pub/gsea/annotations [27].
For each pathway, we used whenever possible multiple
signatures from independent studies, to minimize the possibility
of laboratory-specific effects. For further analyses (e.g. survival
comparisons), we used the mean of activation scores across
independent signatures belonging to the same pathway or group of
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pathways in order to determine the final activation status of the
pathway or group of pathways.
Mapping Pathway Prediction Signatures in Breast
Cancers
Two pathway activation signatures [19,20] (Table S11) related
to the estrogen signaling pathway were analyzed. The breast
cancer cell line dataset [18] was obtained from http://www.ebi.ac.
uk/microarray-as/ae/download/E-TABM-157.raw.zip. Activa-
tion scores for breast cancer cell lines were computed by
comparing each individual line against the median profile of the
collection of 51 breast cancer cell lines. P-values for the validation
of our predictions against ER status were computed using
Pearson’s chi-square test, under the null hypothesis that the
pathway predictor delivers comparable performance to a random
predictor.
Mapping Pathway Prediction Signatures in Gastric
Cancers
20 signatures [9,19,20,22–24,39–49] (Table S12) representing
the activation of 11 pathways related to gastric carcinogenesis were
analyzed. Activation scores for primary GCs were computed by
comparing each individual GC against the median profile of the
patient cohort being analyzed. For the analysis of GC cell lines,
final activation scores were obtained by computing the mean
activation scores across the seven reference profiles (Table S4).
Unsupervised hierarchical clustering (average linkage with cen-
tered Pearson correlation metric) was applied to establish patterns
of co-activation between different pathways using BRB-Array-
Tools.
Pathway Activation Scores
Pathway activation scores were computed using two inputs: 1)
cancer profiles, comprising lists of probesets sorted by differential
gene expression between individual cancer gene expression
profiles and a reference profile (see Text S1), where n is defined
as the total number of probesets in each cancer profile i, and 2) a
query signature QS (pathway activation signature). Probesets
representing either up- (or down-) regulated genes in the QS are
defined as ‘tags’, and t the number of tags in the up- (or down-)
regulated portion of the QS. Raw enrichment scores kidirection were
computed using a Kolmogorov-Smirnov metric previously de-
scribed in [37]. Here, ‘direction’ in kidirection may be considered as
‘up’ or ‘down’, depending on whether the set of tags in question
represents the up-regulated (kiup) or the down-regulated (k
i
down)
portion of the QS. For a cancer profile i and a set of t QS tags, the
position of tag j in the cancer profile i is defined as V(j), forming the
vector V.
V~ V 1ð Þ V 2ð Þ . . . V tð Þ½  ð1Þ
The elements of V are then sorted in ascending order of V(j) such
that V 1ð ÞƒV 2ð Þƒ . . .ƒV t{1ð ÞƒV tð Þ. In this manner, the
tags indexed by j are ordered based on their position in the cancer
profile (e.g. tag 1 is the probeset with the highest rank in the cancer
profile among all t tags in the up- (or down-) regulated portion of
the QS). Using the sorted elements of V, two parameters are
computed:
a~max
t
j~1
j
t
{
V jð Þ
n
 
ð2Þ
b~max
t
j~1
V jð Þ
n
{
j{1ð Þ
t
 
ð3Þ
If awb, kidirection is set to a. Otherwise, (if bwa), k
i
direction is set to
2b.
To compute the pathway activation score Si, if kiup and k
i
down
have the same signs then Si for cancer profile i is set to zero.
Otherwise, the raw activation score siis obtained.
si~kiup{k
i
down ð4Þ
The maximum and minimum of si across all cancer profiles in the
cohort are defined as p and q, respectively. The activation score Si
is the normalized form of si, where
Si~
si
p
if siw0 ð5Þ
and
Si~{
si
q
if siv0 ð6Þ
In cases where more than one profile exists for a sample, the final
activation score represents the mean activation score across the
replicate profiles.
Reference profiles. For primary gastric tumor and breast
cancer profiles, activation scores were computed using the median
profile of the cohort as the reference profile. The median profile
was obtained by computing the median of expression values across
all members of the cohort. For GCCL profiles, we used seven
distinct reference profiles: the median GC cell line profile, a
normal skin fibroblast profile, and five normal stomach profiles
(Table S4). Besides the median GCCL profile, the other reference
profiles were obtained from different cohorts (i.e. different
expression datasets). Details regarding the seven reference
profiles are available in Table S4 and Text S1. Final activation
scores for the GCCLs were obtained by computing the mean
activation scores across the seven reference profiles.
Cell Proliferation Assay
Cell proliferation assays were performed on 22 lines (except
SNU1, SNU5, and SNU16) using a CellTiter96 Aqueous
Nonradioactive Cell Proliferation Assay kit (Promega) following
the manufacturer’s instructions. Briefly, cell lines were plated at
concentrations of 16103 to 56103 cells per well in 96-well plates.
Growth rates, representing proliferative activity, were analyzed
after 48 hours.
Western Blotting Assays and Immunocytochemistry
Western blotting was performed as previously described [50]
using the following antibodies and dilutions: 1:500 b-catenin
(catalogue number 06-734, Upstate), 1:500 TCF7L2 (05-511,
Upstate), 1:1,000 b-actin (sc-8432, Santa Cruz), 1:500 p65 (sc-372,
Santa Cruz), 1:500 p50 (sc-1191, Santa Cruz), and 1:1,000
GAPDH (ab9483, Abcam). Processing of cell line TMAs (tissue
microarrays), blocking, and antigen retrieval was performed as
previously described [51]. p65 antibodies were incubated at a
dilution of 1:50 for 2 hours at 37uC. Signal detection was
performed using the REAL system (DAKO) at 37uC for
30 minutes, using the DAB chromogen (1:50 dilution), and
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Mayer’s haematoxylin counterstain. The slides were scored by an
experienced histopathologist (H.G.) and the percentage of positive
nuclei, percentage of cells with cytoplasmic staining, and staining
intensity were assessed.
Luciferase Reporter Assays
TOPFLASH assays for validation of Wnt/b-catenin activation
were performed as previously described [50]. For validation of NF-
kB activation, MKN1, MKN7, Hs746T, AGS, and SCH cells
were transfected with a pNFkB-Luc reporter (Clontech, Cat.
No. 631904) using FuGENE 6 Transfection Reagent (Roche) in
96-well plates. pNFkB-Luc contains the Photinus pyralis luciferase
gene and multiple copies of the NF-kB consensus sequence fused
to a TATA-like promoter region from the Herpes simplex virus
thymidine kinase promoter. The same cells were also transfected
with pGL4.73[hRluc/SV40] vector (Promega) as a normalization
control. Cells were collected 48 hours after transfection and
luciferase activity was measured using a dual-luciferase reporter
assay system (Promega). All experiments were repeated three
independent times.
Statistical Methods
Kaplan-Meier analysis (SPSS, Chicago) was used for survival
comparisons of patient cohorts where clinical follow-up and
mortality information were available. P-values representing the
significance of the differences in survival outcome (metric: overall
survival) were calculated using the Log Rank (Mantel-Cox) test,
with p-values of ,0.05 being considered significant. Cox
regression models were used for computing hazard ratios and
implementing multivariate analyses including combined status of
two pathways and overall tumor stage (TNM classification: 1–4) as
variables. Patients from Cohorts 1 and 2 analyzed in survival
comparisons exhibit a significant relationship between overall
survival and overall tumor stage, suggesting that patient selection is
likely non-biased (data not shown). P-values denoting the
significance of a correlation coefficient R between two N-element
vectors were estimated from the Student t-distribution, against the
null hypothesis that the observed value of t =R/![(12R2)/(N22)]
comes from a population in which the true correlation coefficient
is zero. Unless otherwise specified, all other p-values (used in
comparisons of two groups) were computed using Student’s t-test.
All p-values are two-tailed. Gene Set Enrichment Analysis (GSEA)
was performed as described in Subramanian et al. [27].
Supporting Information
Figure S1 Predictions using pathway signatures or key pathway
genes. (A–C) Cell proliferation predictions. Experimentally
determined proliferative capacities of GC cell lines were compared
against predictions by (A) Myc gene expression, (B) E2F1 gene
expression, and (C) the mean activation score from proliferation/
stem cell pathway signatures. Both Myc and E2F1 are key
proliferation pathway genes. The y-axis represents true prolifer-
ative capacity, and the x-axis represents the predictions. While
there is no significant correlation using E2F1 or Myc as predictors
(p.0.05 in both cases) (A and B), the mean proliferation/stem cell
signature score is significantly correlated with proliferative
capacity (p = 0.0278) (C) and Figure 4A in Main Text. (D–F)
Wnt pathway predictions. Wnt pathway activity was determined in
GC cell lines using a TCF4 (aka TCF7L2)-luciferase reporter assay
(see Materials and Methods), and compared against predictions by
(D) TCF4 gene expression, (E) b-catenin gene expression, and (F)
the mean activation score from Wnt/b-catenin signatures. Both
TCF4 and b-catenin are key Wnt pathway genes. The y-axis
represents true Wnt activity, while the x-axis represents the
predictions. While there is no significant correlation using TCF4
or b-catenin as predictors (p.0.05 in both cases) (D and E), the
mean Wnt/b-catenin signature activation score is significantly
correlated with Wnt activity (p = 0.0380) (F).
Found at: doi:10.1371/journal.pgen.1000676.s001 (0.05 MB
DOC)
Figure S2 Using multiple references to obtain high-confidence
prediction of the activation status of the NF-kB pathway. GCCLs
ranked top (or bottom) five via at least one of the two NF-kB
signatures and at least seven times across all references and
signatures were chosen as GCCLs in which the NF-kB pathway is
called as activated (‘NF-kB/on’) (or nonactive (‘NF-kB/off’)). Only
GCCLs consistently predicted as NF-kB-activated (or NF-kB-
nonactive) were chosen for further dry lab and wet bench analyses.
Found at: doi:10.1371/journal.pgen.1000676.s002 (0.10 MB
DOC)
Figure S3 NF-kB immunocytochemistry in gastric cancer cell
lines. (A) MKN1 cells show strong cytoplasmic staining in most
cells, and nuclear expression of NF-kB in a subset of cells (blue
arrow). (B) Hs746T cells show strong cytoplasmic staining in all
cells. No nuclear expression of NF-kB. (C) AGS cells show weak
cytoplasmic staining in all cells. No nuclear expression of NF-kB.
(D) SCH cells show weak cytoplasmic staining in all cells. No
nuclear expression of NF-kB. (Chromogen used: DAB (brown),
Mayer’s haemalaun counterstain (blue), Scale bar = 30 mm)
Found at: doi:10.1371/journal.pgen.1000676.s003 (7.22 MB
DOC)
Figure S4 p50 and p65 gene expression in GCCLs. Gene
expression values for p50 and p65 (log10 transformed) across 11
GCCLs were compared. p50 values are plotted as yellow columns,
while p65 values are in black. The y-axis represents expression
values, while individual GCCLs are on the x-axis sorted by
expression level. The range in p50 gene expression is 0.54 or 3.49-
fold (100.54 = 3.49), while the range in p65 expression is 1.04 or
10.94-fold. Thus, there is a 3.136 greater degree of range in p65
expression than in p50 expression.
Found at: doi:10.1371/journal.pgen.1000676.s004 (0.03 MB
DOC)
Table S1 Prediction accuracies of estrogen signaling related
signatures. (A) Predictions using the breast-derived ‘tamoxifen
sensitivity’ signature. (B) Predictions using the osteosarcoma-
derived ‘estrogen response’ signature.
Found at: doi:10.1371/journal.pgen.1000676.s005 (0.03 MB
DOC)
Table S2 Membership of the signatures, determined using
unsupervised hierarchical clustering in each of the three GC
cohorts.
Found at: doi:10.1371/journal.pgen.1000676.s006 (0.04 MB
DOC)
Table S3 Pathway activation frequencies in GC.
Found at: doi:10.1371/journal.pgen.1000676.s007 (0.03 MB
DOC)
Table S4 Reference profiles for gastric cancer cell lines
(GCCLs). (A) Descriptions of reference profiles. (B) Pearson
correlation values between activation scores from seven different
reference profiles used to generate GCCL activation profiles.
Found at: doi:10.1371/journal.pgen.1000676.s008 (0.04 MB
DOC)
Table S5 Summary of results from IHC assay.
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Found at: doi:10.1371/journal.pgen.1000676.s009 (0.03 MB
DOC)
Table S6 Multivariate analysis for tumor stage (TNM classifi-
cation) and combined activation levels of proliferation/stem cell
and NF-kB pathways in primary tumors.
Found at: doi:10.1371/journal.pgen.1000676.s010 (0.04 MB
DOC)
Table S7 Multivariate analysis for tumor stage (TNM classifi-
cation) and combined activation levels of proliferation/stem cell
and Wnt/b-catenin pathways in primary tumors.
Found at: doi:10.1371/journal.pgen.1000676.s011 (0.04 MB
DOC)
Table S8 Histopathological data for Cohort 1 of 70 tumors from
Australia.
Found at: doi:10.1371/journal.pgen.1000676.s012 (0.14 MB
DOC)
Table S9 Histopathological data for Cohort 2 of 200 tumors
from Singapore.
Found at: doi:10.1371/journal.pgen.1000676.s013 (0.36 MB
DOC)
Table S10 Histopathological data for Cohort 3 of 31 tumors
from the United Kingdom.
Found at: doi:10.1371/journal.pgen.1000676.s014 (0.07 MB
DOC)
Table S11 Signatures associated with perturbed estrogen
signaling.
Found at: doi:10.1371/journal.pgen.1000676.s015 (0.03 MB
DOC)
Table S12 Signatures associated with 11 oncogenic pathways
implicated in gastric carcinogenesis.
Found at: doi:10.1371/journal.pgen.1000676.s016 (0.07 MB
DOC)
Text S1 Supplementary methods.
Found at: doi:10.1371/journal.pgen.1000676.s017 (0.05 MB
DOC)
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